BioCentury | Jul 18, 2020
Translation in Brief

Fate licenses rejection-resistant T cell therapies; plus a marker for anti-PD-1 treatment responsiveness, a cell proliferation control switch and more

Baylor’s engineered T cells designed to avoid immune rejection Baylor College of Medicine has granted Fate Therapeutics Inc. (NASDAQ:FATE) an exclusive license to alloimmune defense receptors, which render allogeneic cell therapies resistant to host immune...
BioCentury | Jun 12, 2020

June 11 Quick Takes: Biotech swept up in sell-off; plus Simcere, Lantern, Cue Health, C2i, BaseLaunch, Sanofi-Cathay and 4BIO

Biotech tumbles as U.S. indexes plunge Biotech indexes fell along with the broader markets Thursdays in a sell-off sparked by fears of an increase in COVID-19 infections. The NASDAQ Composite, S&P 500 and Dow Jones...
BioCentury | Jun 2, 2020

CAR T play Legend looks to lead trio of biotechs onto NASDAQ

Look for three biotechs to price IPOs on NASDAQ this week, with CAR T company Legend the headliner. The Nanjing-based company, which is spinning out of GenScript Biotech Corp. (HKSE:1548), aims to raise $350 million...
BioCentury | May 23, 2020
Product Development

TIGIT breaks through as next-generation checkpoint target

Next-generation checkpoint inhibitors will take the limelight at the 2020 virtual ASCO meeting, with all eyes on TIGIT as the first to back up the noise with data. Genentech is poised to present Phase II...
BioCentury | May 16, 2020
Product Development

Daily Chart: ide-cel’s challengers in the BCMA pipeline

Wednesday’s refusal-to-file letter for idecabtagene vicleucel slows the cell therapy from bluebird bio Inc. and Bristol Myers Squibb Co. in the race to market a product targeting BCMA to treat multiple myeloma (see “Refusal-to-File Letter...
BioCentury | May 15, 2020
Product Development

TIGIT emerges as a standout next generation checkpoint target at ASCO

Drugmakers have been searching for the next checkpoint inhibitor ever since CTLA-4 and PD-1 triggered the immuno-oncology movement roughly five years ago; however, most have disappointed in the clinic. New data presented at the 2020...
BioCentury | May 14, 2020

May 13 Quick Takes: MyoKardia raises $551M; plus Legend looks to NASDAQ for IPO and ADC, Travecta, QureBio, Kintor, Lantern, Kiromic

MyoKardia prices follow-on at a premium MyoKardia Inc. (NASDAQ:MYOK) raised $551.3 million late Tuesday through the sale of 5.3 million shares at $105 in a bumped-up offering that stands to be the biggest follow-on of...
BioCentury | May 13, 2020

Refusal-to-file letter for BMS-bluebird cell therapy further muddies chances of Celgene payout

Partners BMS and bluebird are insistent that FDA’s refusal-to-file letter for their BCMA-targeting cell therapy is merely the result of a documentation issue that isn’t representative of any larger problem. But the resulting delay, which...
BioCentury | May 12, 2020

bluebird hopes tough choices today will keep core programs on track

To ensure it can meet its goal of launching four programs by 2022 amid the coronavirus crisis, bluebird has retooled its BCMA CAR T deal with Bristol Myers, opting for $200 million of cash now...
BioCentury | May 6, 2020

Extended review of Bristol’s CAR T leaves little daylight for CVR from Celgene deal

The latest delay in the regulatory timeline for BMS’s CAR T therapy liso-cel means that any further snags would jeopardize a potential payout worth up to $6.8 billion to Celgene’s shareholders that was associated with...
Items per page:
1 - 10 of 790